Amer Zeidan: Our 2nd International Consortium for MDS

Amer Zeidan shared a post on X:   .

“Our 2nd International Consortium for MDS (icMDS) meeting in Boston (iwMDS/MPN) was very successful with steady progress in achieving our 10 top priority research goals (2022-2032) released with 1st meeting in 2022. We remain united and committed to productive collaborations between all stakeholders.”

Source: Amer Zeidan/X

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center.

Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.